Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 10/20 | 0.52 |
| ▸ | CNR1 | P21554 | 6/20 | 0.52 |
| ▸ | PIM1 | P11309 | 1/20 | 0.39 |
| ▸ | CLK2 | P49760 | 1/20 | 0.39 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.33 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5047222 | 1.00 | CNR2 (0.52) | CNR2CNR1PIM1CLK2CLK4 | |
| SCHEMBL1613913 | 0.97 | CNR2 (0.53) | CNR2CNR1PIM1CLK2CLK4 | |
| SCHEMBL1613910 | 0.97 | CNR2 (0.53) | CNR2CNR1PIM1CLK2CLK4 | |
| SCHEMBL961884 | 0.92 | CNR2 (0.61) | CNR2CNR1PIM1CLK2CLK4 | |
| SCHEMBL961886 | 0.92 | CNR2 (0.61) | CNR2CNR1PIM1CLK2CLK4 | |
| SCHEMBL961906 | 0.90 | CNR2 (0.54) | CNR2CNR1PIM1CLK2CLK4 | |
| SCHEMBL961905 | 0.90 | CNR2 (0.54) | CNR2CNR1PIM1CLK2CLK4 | |
| SCHEMBL962311 | 0.86 | CNR2 (0.53) | CNR2CNR1HSD11B1ALDH1A1TSHR | |
| SCHEMBL962313 | 0.86 | CNR2 (0.53) | CNR2CNR1HSD11B1ALDH1A1TSHR | |
| SCHEMBL961901 | 0.84 | CNR2 (0.49) | CNR2CNR1PIM1CLK2CLK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080064699-A1 | Such as N-[3-(2-methoxyethyl)-1,3-thiazol-2(3H)-ylidene]adamantane-1-carboxamide; neuropathic, nociceptive and/or inflammatory pain; neuroprotection | ABBVIE INC. | 2008-03-13 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080064699-A1 | Such as N-[3-(2-methoxyethyl)-1,3-thiazol-2(3H)-ylidene]adamantane-1-carboxamide; neuropathic, nociceptive and/or inflammatory pain; neuroprotection | OPRL1, OPRK1, OPRD1 | CNR2 5/4885CNR1 10/4885PIM1 1914/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.